Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-08-21, Stock:NVS, The news for the past five days is as follows:
2018-08-14: NEWS1: Three expansions, 923 jobs: Durham County approves incentives packages.NEWS2: Array BioPharma Inc. (ARRY) Q4 2018 Earnings Conference Call Transcript.NEWS3: Regeneron's 12-Week Eylea Dose Gets CRL From FDA for Wet AMD.NEWS4: Regeneron's 12-Week Eylea Dose Gets CRL From FDA for Wet AMD.NEWS5: Regeneron&apos;s 12-Week Eylea Dose Gets CRL From FDA for Wet AMD.NEWS6: Pfizer Expected to Report Robust EPS Rise in Fiscal 2018.NEWS7: What Drove GlaxoSmithKline’s Consumer Healthcare Segment in Q2.NEWS8: The Swiss Stock Market Clung To A Small Increase.NEWS9: The Swiss Stock Market Clung To A Small Increase.NEWS10: Pfizer Is Expected to Report Modest Revenue Rise in Fiscal 2018.NEWS11: GlaxoSmithKline’s Pharmaceuticals Segment in Q2 2018.NEWS12: Novartis recruits new compliance head from Siemens after ethics stumbles.
2018-08-15: NEWS1: A Performance Overview of Bausch + Lomb.NEWS2: Novartis Breaks Below 200-Day Moving Average - Notable for NVS.NEWS3: Novartis Breaks Below 200-Day Moving Average - Notable for NVS.
2018-08-16: NEWS1: FDA Approves Teva’s Generic Version of EpiPen, Stock Up 7.5%.NEWS2: FDA approves first rival generic EpiPen, sending Teva shares up 6%.NEWS3: Mylan’s North America Sales Down 22% in Q2 2018: What’s Next?.NEWS4: MYL Stock Down ~3% since Its Q2 2018 Results on August 8.NEWS5: The Swiss Stock Market Climbed On Trade Deal Hopes.NEWS6: The Swiss Stock Market Climbed On Trade Deal Hopes.NEWS7: Analysts Cut Target Prices on MYL Stock after Its Q2 2018 Results.NEWS8: Market Morning: Gene Therapy Deregulation, Amazon to the Movies, SEC On Musk’s Tail.
2018-08-17: NEWS1: Merck, Eisai Get FDA Approval for Lenvima Label Expansion.NEWS2: Merck, Eisai Get FDA Approval for Lenvima Label Expansion.NEWS3: Mylan’s EpiPen Supply Shortages Continue: What to Expect Ahead.NEWS4: Array BioPharma Missed Sales Estimates for Q4 2018.NEWS5: Mylan’s Q2 Profit Fell against Backdrop of US Market Dynamics.NEWS6: The Swiss Stock Market Clung To A Small Gain.NEWS7: The Swiss Stock Market Clung To A Small Gain.NEWS8: ARAY Reports Record Revenue, PTIE Bleeds, EVOK To Face FDA In April.NEWS9: ARAY Reports Record Revenue, PTIE Bleeds, EVOK To Face FDA In April.
2018-08-20: NEWS1: LCI Whacked On Contract Loss, CWBR Awaits Data, Busy Months Ahead For PLSE.NEWS2: LCI Whacked On Contract Loss, CWBR Awaits Data, Busy Months Ahead For PLSE.NEWS3: Regeneron's Eylea Gets FDA Nod for Wet AMD as a 12-Week Dose.NEWS4: Regeneron's Eylea Gets FDA Nod for Wet AMD as a 12-Week Dose.NEWS5: Amgen Stock Up This Year So Far: Will the Rally Continue?.NEWS6: Amgen Stock Up This Year So Far: Will the Rally Continue?.NEWS7: Regeneron&apos;s Eylea Gets FDA Nod for Wet AMD as a 12-Week Dose.NEWS8: Novan Rallies On Positive Early Results For Inflammatory Skin Disease Medication.NEWS9: Mylan Cuts Its Fiscal 2018 Guidance, Citing US Market Challenges.NEWS10: Mylan Has a Strong Balance Sheet despite Weak Q2 Performance.NEWS11: The Swiss Stock Market Rose On Hopes For Trade Agreement.NEWS12: The Swiss Stock Market Rose On Hopes For Trade Agreement.NEWS13: Novan Announces Promising Clinical Results with SB414.

Answer: Rise